What is your approach to abbreviated DAPT in post-PCI patients (ACS and non-ACS) with high bleeding risk?

Current guidelines suggest dual antiplatelet therapy (DAPT) for a minimum of 6 months after PCI for patients undergoing PCI for stable CAD (non-ACS) and 1 year of DAPT after PCI for patients undergoing PCI for ACS. Patients at higher bleeding risk (HBR) after PCI, however, may not be able to tolerate DAPT for that period of time. For patients at HBR undergoing PCI for non-ACS and ACS indications, it is reasonable and safe to consider shorter courses of DAPT to minimize the time of exposure to DAPT. There have been several studies showing that shorter courses of DAPT (as short as one month) is non-inferior to standard DAPT courses in terms for ischemic and bleeding complications. The Xience Skypoint DES (Abbott) and the Resolute Onyx DES (Me...